Smallpox cost-effectiveness of therapy

Smallpox Microchapters

Home

Patient Information

Overview

Historical Perspective

Eradication

Post-Eradication

Pathophysiology

Causes

Differentiating Smallpox from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Outbreak Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case Studies

Smallpox cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Smallpox cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Smallpox cost-effectiveness of therapy

CDC on Smallpox cost-effectiveness of therapy

Smallpox cost-effectiveness of therapy in the news

Blogs on Smallpox cost-effectiveness of therapy

Directions to Hospitals Treating Smallpox

Risk calculators and risk factors for Smallpox cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  João André Alves Silva, M.D. [2]

## Overview[edit | edit source]

The efforts made to eradicate smallpox were cost-effective given the high morbidity and mortality associated with smallpox.

## Cost-Effectiveness of Therapy[edit | edit source]

Since there is no available antiviral treatment for smallpox, the vaccine is the only potential cost.[1]

In the past, the development and distribution of the bifurcated needle represented one of the costs. This needle improved the ease and diminished the cost of vaccination. About 1,000 needles cost about $5. The needle could be boiled and reused multiple times. Also, since these needles required a smaller amount of vaccine, each vial with the vaccine could now vaccinate 4 times as many people. This was an important achievement since there were certain countries that could not afford any sort of vaccination above a very minimal cost.

## References[edit | edit source]

1. ↑ Moore, Zack S; Seward, Jane F; Lane, J Michael (2006). "Smallpox". The Lancet. 367 (9508): 425–435. doi:10.1016/S0140-6736(06)68143-9. ISSN 0140-6736.

Template:WH Template:WS